CSIMarket Company Name, Ticker, Competitors, else..
 
Medicinova Inc   (NASDAQ: MNOV)
Other Ticker:  
 
 
Price: $1.5600 $0.02 1.299%
Day's High: $1.56 Week Perf: 4 %
Day's Low: $ 1.49 30 Day Perf: 4.7 %
Volume (M): 5 52 Wk High: $ 2.55
Volume (M$): $ 7 52 Wk Avg: $1.64
Open: $1.55 52 Wk Low: $1.12



 Market Capitalization (Millions $) 75
 Shares Outstanding (Millions) 48
 Employees 13
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Medicinova Inc
Medicinova Inc. is a biopharmaceutical company headquartered in La Jolla, California. The company is focused on the development and commercialization of innovative therapeutics for the treatment of serious diseases with high unmet medical needs.

Medicinova was founded in 2000 by Dr. Yuichi Iwaki, and has since grown to become a leading player in the field of biopharmaceutical research and development. The company's research projects are primarily focused on developing therapeutics for the treatment of neurological and autoimmune diseases, with an emphasis on neurological disorders such as multiple sclerosis and neurological pain.

Among their most notable products is MN-166 (ibudilast), which has shown promising results in the treatment of a range of neurological disorders, including multiple sclerosis, neuropathic pain, and addiction. Medicinova also has a pipeline of other promising drug candidates, including MN-001 (tipelukast) for the treatment of nonalcoholic steatohepatitis (NASH) and MN-221 (bedoradrine), a selective beta-2 adrenergic receptor agonist for the treatment of acute exacerbations of asthma.

Since its founding, Medicinova has maintained a strong commitment to advancing the development of safe and effective therapeutics for the treatment of debilitating diseases. The company has received numerous awards for its contributions to the biopharmaceutical industry, including the Frost & Sullivan Global Product Line Strategy Leadership Award for MS Therapeutics in 2018.

Medicinova's team of scientists, researchers, and industry experts are driven by a shared commitment to achieving breakthroughs in the treatment of serious diseases, making the company a leader in the biopharmaceutical space.


   Company Address: 4275 Executive Square La Jolla 92037 CA
   Company Phone Number: 373-1500   Stock Exchange / Ticker: NASDAQ MNOV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        9.33% 
ABT   -0.79%    
BMY   -2.13%    
JNJ   -1.49%    
MRK        6.28% 
PFE        3.99% 
• View Complete Report
   



Clinical Study

Exploring the Expanded Access Program for MN-166 in Amyotrophic Lateral Sclerosis Insights from MediciNovas First Pa...

Published Wed, Apr 9 2025 6:39 AM UTC

AbstractThe landscape of drug development in neurodegenerative diseases is continually evolving, marked by innovative approaches such as the Expanded Access Program (EAP). This article analyzes the recent enrollment of the first patient in an EAP trial evaluating MN-166 (ibudilast) for patients with amyotrophic lateral sclerosis (ALS) by MediciNova, Inc. In light of the com...
Clinical Study

Promising Interim Findings from MediciNovas Phase 2/3 Trial of MN-166 in ALS Presented at International Symposium

Published Thu, Dec 5 2024 11:00 PM UTC

Abstract: MediciNova, Inc., a biopharmaceutical firm listed on both NASDAQ and the Tokyo Stock Exchange, has shared an update regarding its ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) for treating Amyotrophic Lateral Sclerosis (ALS). This announcement was made in anticipation of MediciNova s presentation at the 35th International Symposium on ALS/MND, scheduled f...
Clinical Study

MediciNovas Corporate Update Navigating Challenges and Strategic Development in ALS Treatment

Published Tue, Nov 19 2024 2:01 PM UTC

Abstract This article presents a overview of MediciNova Inc?s recent corporate progress outlined by CEO Yuichi Iwaki, amidst its financial performance in the evolving therapeutic landscape for Amyotrophic Lateral Sclerosis (ALS). The focus will be on the implications of the NIH-funded Phase 2-3 Expanded Access study related to the COMBAT-ALS trial and the company s ongoin...
Management Announcement

MediciNova on the Brink: Navigating Legal Settlements and Clinical Ambitions Amid Financial Strains

Published Mon, Nov 11 2024 11:00 PM UTC

In a noteworthy turn of events for MediciNova, Inc., a biopharmaceutical company based in La Jolla, California, the firm has received notification regarding monetary damages stemming from a patent settlement involving Sanofi and Novartis. This development, announced on November 11, 2024, indicates that MediciNova stands to gain a financial boost from this settlement, althoug...
Clinical Study

MN-166 (Ibudilast) A Promising Multi-Disease Therapeutic Candidate for ALS and Glioblastoma,

Published Mon, Sep 30 2024 1:00 PM UTC

MediciNova?s MN-166 (Ibudilast) in ALS and Glioblastoma: Expansion, Recognition, and Promising Data Abstract MediciNova, Inc., a biopharmaceutical company, continues to advance its investigational drug MN-166 (ibudilast) in multiple therapeutic areas, most notably Amyotrophic Lateral Sclerosis (ALS) and Glioblastoma (GBM). This overview consolidates the latest developments ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com